LMNCdiff-01 is under clinical development by Lumen Bioscience and currently in Phase I for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase I drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LMNCdiff-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LMNCdiff-01 overview
LMN-Cdiff01 is under development for the treatment of clostridium difficile induced colitis. It is administered by the oral route as capsules. The drug candidate is being developed based on the Spirulina technology platform.
Lumen Bioscience overview
Lumen Bioscience is a developer of oral antibody therapeutics. Lumen Bioscience is headquartered in Seattle, Washington, the US.
For a complete picture of LMNCdiff-01’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.